Kevin Reilly
About Kevin Reilly
Kevin Reilly, age 35, is an independent Class II director at Kestra Medical Technologies (KMTS), serving on the Compensation Committee; the board’s director table lists “Director Since Fiscal Year 2024,” while his biography states he “has been a member of our Board since 2025,” a disclosure inconsistency worth noting. He is Managing Director and Head of MedTech for Ally Bridge Group’s private equity strategy (since 2021) and previously was a Principal at CRG (2014–2021) after starting his career in Stifel’s Healthcare Investment Banking group; he holds a B.S. in Finance and Information Systems from the University of Maryland. He is deemed independent under Nasdaq rules; in FY2025 the Board met twice and all directors met the 75% attendance threshold.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Ally Bridge Group | Managing Director; Head of MedTech (PE strategy) | 2021–present | Leads medtech transactions across healthcare subsectors |
| CRG (healthcare investment management) | Principal | 2014–2021 | Growth capital via long-term debt and equity |
| Stifel | Healthcare Investment Banking (early career) | — | Coverage in healthcare investment banking |
External Roles
- No other current public company directorships are disclosed for Mr. Reilly in the proxy; his biography notes prior service “as a director of a number of healthcare companies” without naming entities or dates.
Board Governance
- Committee assignments: Member, Compensation Committee; Chair: Raymond W. Cohen. No changes expected to Compensation Committee composition following the 2025 Annual Meeting.
- Independence: Board determined all directors other than CEO Brian Webster and GC/CAO Traci S. Umberger are independent under Nasdaq standards (includes Mr. Reilly).
- Attendance: Board met twice in FY2025; each director attended at least 75% of meetings; committees were established at IPO and held no FY2025 meetings.
- Lead board roles: Jeffrey Schwartz serves as Chairman; he also chairs Nominating & Corporate Governance.
- Tenure: Disclosure inconsistency—director table shows “Director Since Fiscal Year 2024,” biography says “member of our Board since 2025.”
Fixed Compensation
| Component | Amount | Notes |
|---|---|---|
| Annual retainer – non‑employee director | $60,000 | Pro‑rated for partial year of service |
| Compensation Committee – member retainer | $9,000 | Non‑chair member |
| Compensation Committee – chair retainer | $18,000 | For chair (not applicable to Reilly) |
| Audit Committee – member/ chair | $12,000 / $25,000 | Not applicable to Reilly in FY2025 |
| Nominating Committee – member/ chair | $6,000 / $12,000 | Not applicable to Reilly in FY2025 |
FY2025 actual cash fees received (pro‑rated from IPO to Apr 30, 2025):
| Director | Fees Earned (Cash) |
|---|---|
| Kevin Reilly | $10,397 |
- Reimbursement of reasonable expenses (travel, food, lodging) provided.
Performance Compensation
| Equity Vehicle | Grant Value | Vesting | Notes |
|---|---|---|---|
| Annual RSU grant (non‑employee directors) | $185,000 | Fully vests on 1‑year anniversary | Awarded to directors serving as of and continuing after the annual meeting; forfeited if service ends before vesting |
- No director meeting fees disclosed; no performance‑conditioned director equity awards are described; vesting is time‑based.
- In FY2025, only certain directors (Cohen, Ladone) held restricted shares resulting from conversion of prior partnership units at IPO; no outstanding stock/option awards were reported for Mr. Reilly as of Apr 30, 2025.
Other Directorships & Interlocks
| Topic | Disclosure |
|---|---|
| Compensation Committee interlocks | None; no Kestra executive served on another entity’s comp committee with any Kestra comp committee member. |
| Related‑party oversight | Audit Committee reviews and approves related‑party transactions per policy. |
Expertise & Qualifications
- Healthcare private equity and credit investing (Ally Bridge Group; CRG).
- Early-career healthcare investment banking (Stifel).
- Education: B.S. in Finance and Information Systems, University of Maryland.
Equity Ownership
| Holder | Shares Beneficially Owned | % Ownership | Notes |
|---|---|---|---|
| Kevin Reilly | — (no share count listed in table) | — | Footnote provides address; no holdings number shown for Mr. Reilly in beneficial ownership table (implies no reportable position <1%). |
- Insider Trading Policy prohibits short sales, options transactions, hedging/monetization strategies, holding on margin, or pledging Kestra shares—reduces alignment risks from hedging/pledging.
Governance Assessment
-
Strengths
- Independent director with relevant healthcare investment expertise; serves on an all‑independent Compensation Committee.
- Board determined independent status under Nasdaq; independent directors meet in executive session.
- Attendance threshold met in FY2025; committees instituted at IPO; governance policies in place (Code of Conduct, Corporate Governance Guidelines).
- Clawback policy adopted at IPO per Nasdaq/Exchange Act 10D; comprehensive Insider Trading Policy prohibiting hedging/pledging.
-
Risks and monitoring items
- Ownership alignment: No beneficial ownership disclosed for Mr. Reilly as of July 7, 2025; alignment expected to improve if he receives the standard $185k annual RSU grant at/after the 2025 Annual Meeting.
- Potential conflicts: Mr. Reilly leads medtech investing at Ally Bridge Group; while no related‑party transactions with ABG are disclosed, ongoing monitoring is warranted given Kestra’s audit‑committee‑overseen related‑party policy.
- Board control context: Bain Capital affiliates own ~52.6% of shares and the Chairman (Schwartz) is Bain Capital’s Global PE COO—heightens need for strong independent director oversight on compensation and governance.
-
Disclosure inconsistency
- “Director Since” shows FY2024 in the director table but “member since 2025” in Mr. Reilly’s biography; advisable to clarify this discrepancy with the company.
Appendix: Company‑Level Director Compensation Table (FY2025 excerpt)
| Name | Fees Earned or Paid in Cash ($) | Stock Awards ($) | Option Awards ($) | Total ($) |
|---|---|---|---|---|
| Kevin Reilly | 10,397 | — | — | 10,397 |
Policy References
- Director Compensation Policy details (annual cash retainers and committee fees) and annual RSU structure are summarized above.
- Compensation Committee composition and independence align with Nasdaq/SEC requirements; no interlocks reported.
- Clawback and Insider Trading policies in force.